E-mail: Jiri.Schwarz@uhkt.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia
- ALLOGENEIC TRANSPLANTATION FOR MYELOFIBROSIS IN MYELOPROLIFERATIVE DISEASE -A SINGLE CENTER EXPERIENCE
- ANALYSIS OF RISK FACTORS OF 248 PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA AT DIAGNOSIS
- ANALYSIS OF TREATMENT OUTCOME OF ALL PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA (APL): NO DIFFERENCE IN SURVIVAL BEFORE AND AFTER ATRA ERA
- ANGIOGENIC CYTOKINES IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: ASSOCIATION WITH IGVH MUTATION STATUS AND GENETIC ABNORMALITIES
- Association of IgVH mutation status and plasma levels of angiogenic activators in chronic lymphocytic leukaemia: significantly higher bFGF but not VEGF in IgVH mutated patients
- CAN ESTIMATION OF WT-1 IN PERIPHERAL BLOOD HELP US IN MONITORING RESIDUAL DISEASE OF PML/RARA-POSITIVE AML PATIENTS?
- CBFβ/MYH11 Hypomethylation Signature In Patients With Acute Myeloid Leukaemia
- CLONAL EVOLUTION STUDIED BY I-FISH IN B-CLL
- COMBINATION OF IGVH MUTATIONAL STATUS AND GENETIC ABNORMALITIES MAY FURTHER REFINE PROGNOSTIC STRATIFICATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- DIFFERENTIAL DNA METHYLATION IN AML PATIENTS WITH WILD-TYPE AND MUTATED DNMT3A AND PROGNOSTIC IMPACT OF DNA METHYLATION
- DNMT3A MUTATIONS IN INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA
- Druhá celostátní léčebná studie AML-BFM 98 zvýšila úspěšnost v dosažení remise i celkové přežití dětí s akutní myeloidní leukémií v České republice
- Expression Analysis of WT1 Splicing Variants In CML and AML: –5/+KTS as a Novel Candidate for Early Marker of Relapse
- Expression of Four Major WT1 Splicing Variants in AML and CML: Development of Quantitative Real-Time PCRs and Preliminary Results in Patient Samples
- EXPRESSION OF WT-1 IN HUMAN ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
- EXPRESSION OF WT-1, PRAME, RHAMM AND BAALC GENES IN PERIPHERAL BLOOD OF AML PATIENTS AT DIAGNOSIS
- Expression Pattern of WT1 Isoforms in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Severe Aplastic Anemia (SAA)
- First Achievements of MPN&MPNr-EuroNet (COST Action BM0902), a New European Network Dedicated to the Diagnosis of Myeloproliferative Neoplasms and Hereditary Erythrocytosis and Thrombocytosis
- FIRST EUROPEAN JAK2-V617F INTERLABORATORY QUALITY CONTROL STUDY CARRIED OUT BY THE MPN&MPNR-EURONET (COST ACTION BM0902)
- FLT3 TYROSINE KINASE DOMAIN (TKD) MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
- CHRONIC MYELOPROLIFERATIVE DISORDERS WITH THROMBOCYTHEMIA: THROMBOSIS ASSOCIATED WITH INHERITED THROMBOPHILIA OR JAK2 V617F GENE MUTATION
- IDH1 (BUT NOT IDH2) MUTATIONS CAUSE INFERIOR OUTCOME IN PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETICS
- IMMUNO CHEMOTHERAPY (ANTI CD20 AND FLUDARABIN/CYCLOPHOSPHAMIDE) AND HIGH DOSE CHEMOTHERAPY WITH ASCT INCREASES MOLECULAR REMISSION RATE BUT CANNOT PREVENT RELAPSES
- Improving Survival in Patients with Chronic Lymphocytic Leukemia - Population Based Study
- INHIBITORY EFFECT OF THE ANTIBODY TO CD34 MOLECULE ON STEM CELL AND MYELOID LEUKEMIA CELL LINES
- Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&MPNr-EuroNet Study
- JAK2 Mutation and Additional Thrombophilic Markers Predispose to Thrombosis in Myeloproliferative Diseases with Thrombocythemia
- JAK2 MUTATION AND AN ADDITIONAL THROMBOPHILIC STATE ARE MAJOR PROTHROMBOTIC RISK FACTORS IN MYELOPROLIFERATIONS WITH THROMBOCYTHEMIA – DATA FROM A REGISTRY OF ANAGRELIDE-TREATED PATIENTS
- JAK2 V617F MUTATION SCREENING IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS AND CORE BINDING FACTOR ACUTE MYELOID LEUKEMIAS (CBF-AML)
- Long-Term Experience with Anagrelide (Thromboreductin®) In the Treatment of Essential Thrombocythemia: Data from an International Registry
- Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
- Model klinického registru umožňujícího hodnocení léčebné péče: projekt ALERT (Akutní LEukémie – klinický RegisTr)
- Molecular Variability of FLT3/ITD Mutants and Their Impact on the Differentiation Program of 32D Cells: Implications for the Biological Properties of AML Blasts
- MONITORING OF MRD IN PERIPHERAL BLOOD OF AML PATIENTS BY QUANTITATIVE ESTIMATION OF WT-1 LEVEL
- MONOCLONAL ANTIBODY TO CD34 INHIBITS PROLIFERATION AND INDUCES APOPTOSIS OF CD34 STEM AND MYELOID CELL LINES
- MUTATED OR NON-MUTATED? WHICH DATABASE TO CHOOSE WHEN DETERMINING THE IGVH HYPERMUTATION STATUS IN CHRONIC LYMPHOCYTIC LEUKEMIA?
- MUTATIONS OF ASXL1 GENE IN PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETIC PROFILE
- NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
- p53 Inactivation in CLL: Pattern of 110 TP53 Mutations
- PROGNOSTIC SIGNIFICANCE OF TELOMERE LENGTH, MOLECULAR CYTOGENETIC FINDINGS AND IMMUNOPHENOTYPIC FEATURES IN PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA
- REAL-TIME RT-PCR ASSAY USING THE TAQMAN PROBES WITH LNA (LOCKED NUCLEIC ACID) MODIFICATION TO DETERMINE JAK2 GENE V617F MUTATIONS IN MYELOPROLIFERATIVE DISEASES (MPD)
- SECONDARY GENETIC ABERRATIONS AND THEIR EFFECT ON PROGNOSIS IN CORE BINDING FACTOR - ACUTE MYELOID LEUKEMIA (CBF-AML)
- SHORT WT1 VARIANT OF WILMS TUMOR GENE IS EXPRESSED IN LEUKEMIC CELL LINES, PATIENTS WITH AML, MDS AND IN CML BLAST CRISIS
- Sledování klonálního vývoje u B-CLL metodou I-FISH
- TELOMERE LENGTH EVALUATION IN PATIENTS WITH UNTREATED B-CHRONIC LYMPHOCYTIC LEUKEMIA - CORRELATION WITH OTHER MOLECULAR, CYTOGENETIC AND IMMUNOPHENOTYPIC FEATURES
- THE DIFFERENCES IN PROGNOSTIC OUTCOME BETWEEN AML1/ETO AND CBFb/MYH11 POSITIVE AML PATIENTS
- THE IMPACT OF LENGTH AND INTEGRATION SITE OF THE INTERNAL TANDEM DUPLICATION OF FLT3 GENE ON THE CLINICAL OUTCOME OF PATIENTS WITH AML
- THREE CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIAS (CBF-AML) IN A SINGLE PATIENT
- Thrombosis in MPN with Thrombocythemia Is Associated with Higher Platelet Count At the Time of the Event: Data From the Czech Registry of Patients Treated with Anagrelide
- Uplatnění genomiky (molekulární genetiky) v onkohematologii
- WHAT CAN WE CURRENTLY LEARN FROM NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HAEMATOLOGICAL PRACTICE?
- WHOLE GENOME AND TARGETED BISULFITE SEQUENCING REVEALS 3 DNA METHYLATION CLUSTERS AND NEW BIOLOGICALLY RELEVANT HYPERMETHYLATED GENES IN AML PATIENTS
